FY2026 Earnings Forecast for PolyPid Issued By HC Wainwright

PolyPid Ltd. (NASDAQ:PYPD) – Equities research analysts at HC Wainwright upped their FY2026 EPS estimates for shares of PolyPid in a note issued to investors on Monday, June 9th. HC Wainwright analyst B. Folkes now forecasts that the company will earn ($1.09) per share for the year, up from their previous estimate of ($1.10). HC Wainwright has a “Buy” rating and a $13.00 price objective on the stock. The consensus estimate for PolyPid’s current full-year earnings is ($1.79) per share. HC Wainwright also issued estimates for PolyPid’s FY2027 earnings at ($0.51) EPS, FY2028 earnings at $0.21 EPS and FY2029 earnings at $1.62 EPS.

PolyPid (NASDAQ:PYPD) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.10.

Separately, Roth Capital initiated coverage on PolyPid in a research note on Thursday, June 5th. They issued a “buy” rating and a $9.00 price target on the stock. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $11.25.

PolyPid Stock Down 0.9%

Shares of NASDAQ:PYPD opened at $3.43 on Thursday. The firm has a market capitalization of $34.96 million, a P/E ratio of -0.69 and a beta of 1.25. The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.00 and a current ratio of 1.31. The stock has a 50 day moving average price of $2.80 and a 200-day moving average price of $2.92. PolyPid has a 52-week low of $2.30 and a 52-week high of $4.49.

Institutional Investors Weigh In On PolyPid

Several hedge funds have recently bought and sold shares of the business. AIGH Capital Management LLC lifted its holdings in shares of PolyPid by 13.6% during the first quarter. AIGH Capital Management LLC now owns 940,381 shares of the company’s stock valued at $2,548,000 after purchasing an additional 112,514 shares during the last quarter. J. Goldman & Co LP bought a new position in PolyPid during the 4th quarter valued at approximately $391,000. Finally, Rosalind Advisors Inc. raised its stake in PolyPid by 49.9% during the fourth quarter. Rosalind Advisors Inc. now owns 1,018,021 shares of the company’s stock valued at $3,095,000 after buying an additional 338,853 shares during the last quarter. Institutional investors own 26.47% of the company’s stock.

About PolyPid

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.